TREATMENT OF STABILE ISCHEMIC HEART DISEASE: IS CORONARY STENTING SUPERIOR OVER DRUG THERAPY?
https://doi.org/10.25207/1608-6228-2019-26-1-196-208
Abstract
The results of the most discussed randomized trials of percutaneous coronary intervention (PCI) in comparison with drug therapy (COURAGE and FAME 2) and PCI imitation (ORBITA) in patients with stable coronary heart disease are analyzed. Information on the ongoing ISCHEMIA trial is presented. Different points of view are compared concerning the results of the most important PCI research projects. Factors that can distort the results and the possibilities of their elimination are discussed. The main provisions of the American (2017) and European (2018) Guidelines on myocardial revascularization with a focus on PCI in patients with stable coronary heart disease are described.
Conflict of interest: the authors declare no conflict of interest.
About the Authors
Sergei G. Kanorskii
Kuban State Medical University, Ministry of Health of the Russian Federation
Russian Federation
tel.: +7 (918) 355-82- 81; Mitrofana Sedina str., 4, Krasnodar, 350063
Russian Federation
tel.: +7 (918) 355-82- 81; Mitrofana Sedina str., 4, Krasnodar, 350063
Natal’ya V. Smolenskaya
Kuban State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Ibanez B., James S., Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018; 39(2): 119–177. DOI: 10.1093/eurheartj/ehx393
2. Roffi M., Patrono C., Collet J.P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2016; 37(3): 267–315. DOI: 10.1093/eurheartj/ehv320
3. Patel M.R., Calhoon J.H., Dehmer G.J. et al. ACC/ AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2017; 69(5): 570–591. DOI: 10.1016/j.jacc.2016.10.034
4. Patel M.R., Calhoon J.H., Dehmer G.J. et al. ACC/ AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2017; 69(17): 2212–2241. DOI: 10.1016/j.jacc.2017.02.001
5. Boden W.E., O’Rourke R.A., Teo K.K. et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 2007; 356(15): 1503– 1516. DOI: 10.1056/NEJMoa070829
6. Andrews J.P.M., Fayad Z.A., Dweck M.R. New methods to image unstable atherosclerotic plaques. Atherosclerosis. 2018; 272: 118–128. DOI: 10.1016/j.atherosclerosis.2018.03.021
7. Bentzon J.F., Otsuka F., Virmani R., Falk E. Mechanisms of plaque formation and rupture. Circ. Res. 2014; 114(12): 1852–1866. DOI: 10.1161/CIRCRESAHA.114.302721
8. Bønaa K.H., Mannsverk J., Wiseth R. et al. Drug-eluting or bare-metal stents for coronary artery disease. N. Engl. J. Med. 2016; 375(13): 1242–1252. DOI: 10.1056/NEJMoa1607991
9. Pursnani S., Korley F., Gopaul R. et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ. Cardiovasc. Interv. 2012; 5(4): 476–490. DOI: 10.1161/CIRCINTERVENTIONS.112.970954
10. Sedlis S.P., Hartigan P.M., Teo K.K. et al. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. N. Engl. J. Med. 2015; 373(20): 1937–1946. DOI: 10.1056/NEJMoa1505532
11. Toth G., De Bruyne B., Casselman F. et al. Fractional flow reserve-guided versus angiography-guided coronary artery bypass graft surgery. Circulation. 2013; 128(13): 1405–1411. DOI: 10.1161/CIRCULATIONAHA.113.002740
12. De Bruyne B., Pijls N.H., Kalesan B. et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N. Engl. J. Med. 2012; 367(11): 991–1001. DOI: 10.1056/NEJMoa1205361
13. Rajkumar C.A., Nijjer S.S., Cole G.D. et al. Moving the goalposts into unblinded territory: the larger lessons of DEFER and FAME 2 and their implications for shifting end points in ISCHEMIA. Circ. Cardiovasc. Qual. Outcomes. 2018; 11(3): e004665. DOI: 10.1161/ CIRCOUTCOMES.118.004665
14. Boden W.E. Which is more enduring — FAME or COURAGE? N. Engl. J. Med. 2012; 367(11): 1059– 1061. DOI: 10.1056/NEJMe1208620
15. Zhang D., Lv S., Song X. et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention: a meta-analysis. Heart. 2015; 101(6): 455–462. DOI: 10.1136/heartjnl-2014-306578
16. Kitchell J.R., Glover R.P., Kyle R.H. Bilateral internal mammary artery ligation for angina pectoris; preliminary clinical considerations. Am. J. Cardiol. 1958; 1(1): 46–50.
17. Cobb L.A., Thomas G.I., Dillard D.H. et al. An evaluation of internal-mammary-artery ligation by a double-blind technic. N. Engl. J. Med. 1959; 260(22): 1115–1118.
18. Bhatt D.L., Kandzari D.E., O’Neill W.W. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014; 370(15): 1393–1401. DOI: 10.1056/NEJMoa1402670
19. Benjamin E.J., Virani S.S., Callaway C.W. et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018; 137(12): e67–e492. DOI: 10.1161/CIR.0000000000000558
20. Al-Lamee R., Thompson D., Dehbi H.M. et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018; 391(10115): 31–40. DOI: 10.1016/ S0140-6736(17)32714-9
21. King S.B. 3rd, Dickert N.W., Miller F.G. Learning from FAME: the need for sham controls in trials of stable coronary disease. JACC Cardiovasc. Interv. 2014; 7(3): 342–344. DOI: 10.1016/j.jcin.2014.02.001
22. Al-Lamee R., Francis D.P. Swimming against the tide: insights from the ORBITA trial. EuroIntervention. 2017; 13(12): e1373–e1375. DOI: 10.4244/EIJV13I12A217
23. Francis D.P, Al-Lamee R. Percutaneous coronary intervention for stable angina in ORBITA — Authors’ reply. Lancet. 2018; 392(10141): 28–30. DOI: 10.1016/ S0140-6736(18)31190-5
24. De Bruyne B., Fearon W.F., Pijls N.H. et al. Fractional flow reserve-guided PCI for stable coronary artery disease. N. Engl. J. Med. 2014; 371(13): 1208–1217. DOI: 10.1056/NEJMoa1408758
25. Kanorskiĭ S.G., Smolenskaya N.V. Triple antianginal combinations in the treatment of elderly and senile patients with stable angina. Terapevticheskii Arkhiv. 2016; 88(12): 33–40. DOI: 10.17116/terarkh2016881233-40
26. Maron D.J., Hochman J.S., O’Brien S.M. et al. International study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA) trial: rationale and design. Am. Heart. J. 2018; 201: 124–135. DOI: 10.1016/j.ahj.2018.04.011
27. Neumann F.J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart. J. 2018. Aug 25. DOI: 10.1093/ eurheartj/ehy394 [Epub ahead of print]
Review
For citations:
Kanorskii S.G., Smolenskaya N.V. TREATMENT OF STABILE ISCHEMIC HEART DISEASE: IS CORONARY STENTING SUPERIOR OVER DRUG THERAPY? Kuban Scientific Medical Bulletin. 2019;26(1):196-208. (In Russ.) https://doi.org/10.25207/1608-6228-2019-26-1-196-208
Views:
458
Email this article 